US2021361717A1PendingUtilityA1

Mesenchymal cell-derived exosomes to treat neurological disorders

57
Assignee: UNIV RAMOTPriority: Aug 14, 2016Filed: Aug 4, 2021Published: Nov 25, 2021
Est. expiryAug 14, 2036(~10 yrs left)· nominal 20-yr term from priority
Inventors:Daniel OffenNisim Perets
A61P 25/28A61P 25/18A61K 35/28A61K 9/127A61K 9/08A61K 9/0043A61K 9/0019
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating a neurological disease (such as autism) in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of microparticles derived from mesenchymal stem cells.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a neurodevelopmental disorder in a subject comprising administering to the subject a therapeutically effective amount of particles derived from mesenchymal stem cells (MSCs), thereby treating the neurodevelopmental disorder in the subject, wherein the neurodevelopmental disorder is schizophrenia. 
     
     
         2 . The method of  claim 1 , wherein said administering comprises intranasally administering. 
     
     
         3 . The method of  claim 1 , wherein said particles are selected from the group consisting of exosomes, microvesicles, membrane particles, membrane vesicles, ectosomes and exovesicles. 
     
     
         4 . The method of  claim 3 , wherein said particles are exosomes. 
     
     
         5 . The method of  claim 1 , wherein said mesenchymal stem cells are derived from dental pulp. 
     
     
         6 . The method of  claim 1 , wherein said mesenchymal stem cells are derived from bone marrow. 
     
     
         7 . The method of  claim 1 , wherein said mesenchymal stem cells are derived from adipose tissue. 
     
     
         8 . The method of  claim 1 , wherein said MSCs are human MSCs. 
     
     
         9 . The method of  claim 1 , wherein said MSCs are allogeneic. 
     
     
         10 . The method of  claim 1 , wherein said MSCs are non-allogeneic. 
     
     
         11 . A method of treating stroke in a subject in need thereof comprising intranasally administering to the subject a therapeutically effective amount of particles derived from mesenchymal stem cells, thereby treating stroke in the subject. 
     
     
         12 . The method of  claim 11 , wherein said particles are selected from the group consisting of exosomes, microvesicles, membrane particles, membrane vesicles, ectosomes and exovesicles. 
     
     
         13 . The method of  claim 12 , wherein said particles are exosomes. 
     
     
         14 . The method of  claim 11 , wherein said mesenchymal stem cells are derived from dental pulp. 
     
     
         15 . The method of  claim 11 , wherein said mesenchymal stem cells are derived from bone marrow. 
     
     
         16 . The method of  claim 11 , wherein said mesenchymal stem cells are derived from adipose tissue. 
     
     
         17 . The method of  claim 11 , wherein said MSCs are human MSCs. 
     
     
         18 . The method of  claim 11 , wherein said MSCs are allogeneic. 
     
     
         19 . The method of  claim 11 , wherein said MSCs are non-allogeneic.

Join the waitlist — get patent alerts

Track US2021361717A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.